Harvey Investment Co. LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 3.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,619 shares of the biopharmaceutical company’s stock after buying an additional 1,886 shares during the period. Harvey Investment Co. LLC’s holdings in Pfizer were worth $1,714,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in PFE. Thomaspartners Inc. raised its stake in Pfizer by 4.4% in the first quarter. Thomaspartners Inc. now owns 4,814,578 shares of the biopharmaceutical company’s stock valued at $142,704,000 after buying an additional 202,518 shares during the period. Mariner Wealth Advisors LLC raised its stake in Pfizer by 31.2% in the first quarter. Mariner Wealth Advisors LLC now owns 169,724 shares of the biopharmaceutical company’s stock valued at $5,031,000 after buying an additional 40,408 shares during the period. Friess Associates LLC raised its stake in Pfizer by 12,154.7% in the first quarter. Friess Associates LLC now owns 443,620 shares of the biopharmaceutical company’s stock valued at $13,149,000 after buying an additional 440,000 shares during the period. Wellington Management Group LLP raised its stake in Pfizer by 5.0% in the first quarter. Wellington Management Group LLP now owns 82,813,816 shares of the biopharmaceutical company’s stock valued at $2,454,601,000 after buying an additional 3,936,078 shares during the period. Finally, Prudential PLC raised its stake in Pfizer by 2.5% in the first quarter. Prudential PLC now owns 8,008,048 shares of the biopharmaceutical company’s stock valued at $237,359,000 after buying an additional 192,664 shares during the period. Hedge funds and other institutional investors own 68.53% of the company’s stock.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) traded up 0.69% during midday trading on Wednesday, reaching $32.14. 38,519,485 shares of the company’s stock were exchanged. The firm’s 50-day moving average is $31.87 and its 200 day moving average is $34.12. Pfizer Inc. has a 1-year low of $28.25 and a 1-year high of $37.39. The stock has a market cap of $195.04 billion, a P/E ratio of 32.27 and a beta of 0.90.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $0.61 EPS for the quarter, missing the consensus estimate of $0.62 by $0.01. Pfizer had a return on equity of 23.68% and a net margin of 13.09%. The business had revenue of $13.05 billion for the quarter, compared to analyst estimates of $13.05 billion. During the same quarter in the prior year, the firm earned $0.60 EPS. The firm’s quarterly revenue was up 7.9% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post $2.41 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 3.73%. The ex-dividend date is Tuesday, November 8th. Pfizer’s dividend payout ratio is 106.20%.

ILLEGAL ACTIVITY WARNING: “Harvey Investment Co. LLC Increases Stake in Pfizer Inc. (PFE)” was first published by Daily Political and is the propert of of Daily Political. If you are viewing this news story on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this news story can be viewed at http://www.dailypolitical.com/2016/11/30/harvey-investment-co-llc-increases-stake-in-pfizer-inc-pfe.html.

PFE has been the subject of several recent analyst reports. Sanford C. Bernstein set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, August 2nd. Jefferies Group decreased their target price on shares of Pfizer from $40.00 to $39.00 and set a “buy” rating for the company in a research report on Tuesday, September 13th. Argus restated a “buy” rating and issued a $39.00 target price on shares of Pfizer in a research report on Sunday, August 28th. Bank of America Corp. set a $40.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, August 22nd. Finally, Piper Jaffray Cos. set a $54.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, August 23rd. Twelve investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $37.91.

In related news, insider Anthony J. Maddaluna sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $33.00, for a total transaction of $330,000.00. Following the completion of the transaction, the insider now owns 112,087 shares in the company, valued at $3,698,871. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Albert Bourla sold 18,390 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $30.05, for a total transaction of $552,619.50. Following the transaction, the insider now owns 149,199 shares of the company’s stock, valued at approximately $4,483,429.95. The disclosure for this sale can be found here. Insiders own 0.07% of the company’s stock.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.